Jerry Snidow

Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: Results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain

Lynn R. Webster, Jan Peter Jansen, John F. Peppin et al. · Pain · 2008 · 144 citations

Medicine, Pharmacology, Pharmacotherapy +17

A Randomized, Placebo-Controlled Phase 3 Trial (Study SB-767905/013) of Alvimopan for Opioid-Induced Bowel Dysfunction in Patients With Non-Cancer Pain

Gordon Irving, Janos Pénzes, Brian Ramjattan et al. · Journal of Pain · 2011 · 66 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

A Randomized, Placebo-Controlled Phase 3 Trial (Study SB-767905/012) of Alvimopan for Opioid-Induced Bowel Dysfunction in Patients With Non-Cancer Pain

Jan‐Peter Jansen, Daniel Lorch, John Langan et al. · Journal of Pain · 2011 · 66 citations

Medicine, Pharmacology, Pharmacotherapy +17

Evaluation of the impact of highly active antiretroviral therapy on immune recovery in antiretroviral naive patients

Lena Al‐Harthi, John C. Voris, BK Patterson et al. · HIV Medicine · 2004 · 42 citations

Life Sciences, Immunology, Infectious Diseases +17

Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment

Philip Keiser, Michael Sension, Edwin DeJesus et al. · BMC Infectious Diseases · 2005 · 39 citations · Full text

Medicine, Infectious Diseases, Pharmacology +17